ERBB2 and breast cancer: Among the 100 breast cancer lesions of 96 patients in the metastatic group, 16 (16%) were luminal A type, 49 (49%) were luminalB type, 16 (16%) were Her-2 overexpression type, 17 were triple-negative type (17%), and 2 (2.0%) were no molecular typing (incomplete immunohistochemical results).